علیرضا طبیب زاده - Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
محمد امین عباسی - Department of Internal Medicine, Firoozabadi Hospital, Iran University of Medical Sciences, Tehran, Iran
سجاد کرم پور - Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
محمد هادی کربلایی نیا - Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
مریم اسقایی - Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
سید علی جواد موسوی - Department of Pulmonology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
حمید زاهدنسب - Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
پرستو یوسفی - Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
حسین کیوانی - Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

Background and Aims: The current preliminary study aimed to assess the clinical symptoms of the ۶۷ Iranian COVID-۱۹ patients and investigate the possible beneficial effects of the naproxen compared to the standard therapeutic regimen. Materials and Methods: We assessed ۶۷ COVID-۱۹ patients. All COVID-۱۹ cases were confirmed by computed tomography (CT) and real time-polymerase chain reaction tests. We evaluated the clinical symptoms of the patients at the admission time. Also, a group of ۲۸ patients received naproxen besides their standard treatment. Clinical presentations, radiographic features, white blood cells (WBC) in peripheral blood, hemoglobin, platelets, C-reactive protein, erythrocyte sedimentation rate, blood urea nitrogen, lactate dehydrogenase, Albumin, and Creatine Phosphokinase were evaluated. Results: The patients' clinical symptoms show that cough (۸۹.۶%) was the most repeated signed at the admission time, followed by fever at ۷۸.۷%, fatigue at ۷۰%, and myalgia at least ۶۴.۲%. Unilateral slight ground-glass opacity was the most abundant presentation by ۶۴.۱% in CT. The laboratory assessment in patients indicates that mean WBC was ۶۱۹۳ ± ۳۲۵۸ (x۱۰۶ /L), and mean lymphocyte was ۲۷.۸ ± ۱۲%. The survival rate and the hospitalization days for patients with or without the Naproxen regimen were not statistically significant. Conclusion: The most common clinical symptoms in Iranian patients with COVID-۱۹ at the admission time include cough, fever, fatigue, and myalgia. Based on the current study results, the survival rate and the hospitalization days for patients with or without Naproxen usage were not statistically significant. The laboratory parameters could not show any particular statistically significant differences.

COVID-۱۹, Iran, Naproxen, SARS-CoV-۲